Skip to Content
Patient Information Leaflets (PILs)

These Patient Information Leaflets (PILs) are specially written by the British Association of Dermatologists (BAD). A small selection is available in booklet format and can be ordered by filling in an order form.

The BAD has been awarded The Information Standard certification for the process it employs to develop information products aimed at the general public, which include PILs, Sun Awareness Campaign materials, and other information products.

The BAD shall hold responsibility for the accuracy of the information published, and neither the scheme operator nor the scheme owner shall have any responsibility for costs, losses, or direct or indirect damages or costs arising from inaccuracy of information or omissions in information published on the website on behalf of the BAD.

Please note:

  1. There are thousands of different skin complaints, therefore, the focus of the British Association of Dermatologists' PILs production is on the most common, rarest or debilitating skin conditions.
  2. The offer to provide details of source materials used to inform British Association of Dermatologists' PILs is for instances where the advice provided perhaps does not reflect local practice, and not an offer to conduct literature searches or supply bibilographic materials for your own research.
Close
Hydroxychloroquine

Hydroxychloroquine is one of several antimalarial drugs that have anti-inflammatory effects useful in other diseases. It is licensed in the UK for the treatment of malaria.

Hydroxychloroquine is particularly effective for systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE). By reducing inflammation, hydroxychloroquine can decrease pain, swelling and stiffness of joints, and improve or clear some rashes.

Back to top